2 January 2022 in Hemoglobin
Thailand has a population of 66.2 million with 30.0–40.0% of them carrying thalassemia genes. Interaction of these thalassemia genes lead to more than 60 genotypes with a wide spectrum of clinical severity from asymptomatic to lethal. Estimation based on gene frequencies and number of babies born each year, there will be about 1.2% babies born with severe cases of thalassemia each year. Further estimation revealed that 1.0% of the Thai population have thalassemia disease, which is a big health problem for the country. Thalassemia prevention and control programs were introduced using post conception screening in couples and prenatal diagnosis (PND) for the prevention of new thalassemic births. Moreover, the majority of existing cases are undergoing supportive treatment with regular blood transfusions and iron chelation. Curative treatment by hematopoietic stem cell transplantation (HSCT) is available but is limited to a minority of the patients.
2 January 2022 in Hemoglobin
β-Thalassemia (β-thal) is highly prevalent in Myanmar, but limited data are available on the molecular basis and the clinical manifestations in Myanmar patients. In this study, we investigated the clinical features and β-globin gene abnormalities in 15 homozygous β-thal and 60 Hb E (HBB: c.79G>A)/β-thal pediatric patients who attended Yangon Children Hospital, the biggest thalassemia day care unit center in Myanmar. Eight different β0-thal mutations were identified, with four accounting for 88.9% of alleles studied (excluding the Hb E variant). A genotype-phenotype correlation was found; all homozygous β0-thalassemias had severe clinical courses, whereas the highly variable disease severity was demonstrated among Hb E/β0-thal patients. Interactions of IVS-I-1 (G>T) (HBB: c0.92+1G>T) β0-thal with Hb E are associated with milder clinical symptoms. The number of mildly affected Hb E/β-thal patients was lower than expected, suggesting that there may be a considerable number of patients in the population who have either not been admitted to hospital or diagnosed with carrying the disease. Although the clinical severity in the Myanmar β-thal patients seems to be similar to that in other populations, the levels of hemoglobin (Hb) appears to be very low. These findings indicate the need for the improvement of patient management and the development of prevention and control programs for β-thal in Myanmar.
15 April 2017 in ECS Meeting Abstracts
A simple electrochemical aptasensor was developed for the detection of glycated albumin (GHSA) using ssDNA aptamer that selectively binds to GHSA as a recognition element. The biotinylated ssDNA aptamer was immobilized on a streptavidin-modified screen-printed carbon electrode (SPCE). The changes of interfacial features of the electrode surface, which were based on the aptamer-GHSA interaction, were probed in the presence of the redox Fe(CN)6 3- using square wave voltammetry (SWV) measurements (Fig 1). The results showed that limit of detection of our sensor was 3 µg/ml, with a calibration curve to the range of 16 mg/ml. The aptasensor showed high selectivity for GHSA over other molecules that is usually available in the blood. Our aptasensor was successfully applied to detect GHSA in serum samples, which demonstrated the higher levels of GHSA concentrations in diabetes than normal persons. These indicate that our electrochemical aptasensor has a potential for diagnosis and monitoring of diabetes mellitus. Figure 1
30 September 2026 in International Journal of Health Policy and Management
Background: Thalassaemia is a genetic blood disorder endemic in Thailand. Management of severe thalassaemia utilises significant resources posing a substantial socio-economic burden; thus, prevention has been identified as a more sustainable approach to address thalassaemia. This study evaluated the cost-effectiveness and budget impact of various thalassaemia screening strategies in Thailand, including both pre-conception and post-conception approaches. Methods: A cost-effectiveness analysis (CEA), from the Thai healthcare payer’s perspective, was conducted using decision analytic modelling. Decision trees were used to estimate the incremental screening cost per severe thalassaemia birth averted for four main screening strategies compared to "no screening": post-conception screening (Strategy 1), pre-conception screening with targeted deoxyribonucleic acid (DNA) analysis (Strategy 2), pre-conception screening with universal DNA analysis (Strategy 3), and a combination of pre-conception and post-conception screening (Strategy 4). The cost-effectiveness threshold (CET) used was the lifetime cost of managing severe thalassaemia in Thailand. The annual budget impact of the upfront costs of implementing these strategies was also estimated. Results: Strategies 1, 2, and 4 were cost-saving compared to the threshold of the average lifetime cost of managing severe thalassaemia in Thailand, $21,017. Strategy 4 had the lowest screening cost of $6773 [$4522–$10 066] per severe thalassaemia birth averted. Strategy 2 cost $8977 [$5689–$13 956] per severe thalassaemia birth averted, and Strategy 1 cost $10 474 [$7121–$15 734] per severe thalassaemia birth averted. In contrast, Strategy 3 cost $57 692 [$33 240–$96 123] per severe thalassaemia birth averted and is not cost-saving. The annual budget impact of the upfront costs of implementing thalassaemia screening ranged from $1.30 million to $288.93 million, depending on the strategy adopted and uptake rates. Conclusion: Post-conception thalassaemia screening is cost-saving in Thailand. Combining pre-conception and post-conception screening strategies may offer even better value for money in the Thai context, but with a higher upfront cost of implementation.